



Dear Health Care Professional:

United Therapeutics has been closely monitoring the evolving Coronavirus situation and recognizes the particularly devastating impact this outbreak can have on pulmonary hypertension patients, their families, caregivers and healthcare providers. I want to briefly highlight the actions we are taking to ensure both a continuous supply of drug product and ongoing support for patients and healthcare providers.

It has long been a strategic priority of United Therapeutics to ensure a steady, continuous supply of our drug products for current and new patients. To that end, we maintain a minimum two-year supply of Remodulin, Tyvaso, and Orenitram in our warehouses, and we require our specialty pharmacy (SP) distributors to maintain a minimum of 30 days' inventory on hand. We also maintain a minimum four-month supply of Adcirca (currently, we have approximately six months' inventory), which we license from and is manufactured by Eli Lilly. Our manufacturing facilities, both on-premise and back-up sites in the United States, remain fully operational and continue to make additional drug product. We are not at risk of a drug supply shortage.

We are working closely with our SP distributors to ensure continuity of their nursing services for patients using our products. Where needed, SP nurses will continue to be deployed to a patient's home for care, and where possible or requested by the patient, SP will conduct virtual nursing visits via video and/or telephone. Similarly, our Regional Nurse Specialist (RNS) team remains available for virtual meetings and in-servicing for your clinical staff and to ensure hospital staff is educated and trained on the management of PAH patients using our therapies.

We have asked our sales representatives and medical science liaisons to temporarily cease in-person visits to your facility in light of the increased demands on your time for patient care as well as safety concerns. These individuals are working remotely and remain available via phone, text, email or video call for questions and/or support. The United Therapeutics' ASSIST call center (877-864-8437) is open, fully operational and ready to support your staff and patients with the referral process, reimbursement support and patient assistance programs.

Finally, our clinical development work and quest to bring novel and more effective therapies and technologies to pulmonary hypertension patients continues onward during this period. Our clinical development team will continue communicating directly with sites regarding any updates to our clinical trials.

On behalf of everyone at United Therapeutics, thank you for everything you're doing to care for and serve the pulmonary hypertension community during these difficult times. Please reach out to your local sales representative or MSL should you have any questions or require information/support.

Wishing you good health and safety,

Michael

Michael Benkowitz
President & COO
United Therapeutics Corporation
mbenkowitz@unither.com

US/CORP/0193